Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088931 · ClinicalTrials.gov registry record · Phase 1
Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02088931 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 3 participants.
The verdict
NCT02088931, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of the experimental therapy of a single infusion of Regulatory T cells (Tregs). The investigators want to find out what effects, good or bad, Tregs will have on the kidney transplant patients. There are different types of T cells. This study uses Regulatory T cells (Tregs), which are found in the blood and are part of the immune system that stops other immune cells from working. Tregs help to turn off the immune system after other immune cells have finished tackling outside infections, and Tregs keep the immune system in check so that the body does not attack itself. The researchers are hoping that, by giving an infusion of Tregs that the attack on the kidney can be stopped and kidney function will be stabilized. It is not known if the Treg experimental therapy can stop the inflammation in the kidney. In this study, the researchers will take some of Tregs from the patient, multiply them in the laboratory, and then infuse them back into the patient. The procedure used to multiply Tregs is an experimental process performed in the laboratory. Similar procedures done with mice have been shown to reverse inflammation but it is not known whether the results will be the same in humans. This therapy has not yet been done in humans outside of a research study.
Interventions
- BIOLOGICAL Treg infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02088931
The ClinicalTrials.gov registry entry for NCT02088931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treg infusion is the first listed.
NCT02088931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02088931 about?
NCT02088931 is a clinical study titled "Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation". The purpose of this study is to test the safety of the experimental therapy of a single infusion of Regulatory T cells (Tregs). The investigators want to find out what effects, good or bad, Tregs will have on the kidney transplant patients. There are different types of T cells. This study uses Regu...
What is the current status of trial NCT02088931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-03. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02088931?
The interventions under investigation include: Treg infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02088931?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.